Edition:
United States

Bioblast Pharma Ltd (ORPN.OQ)

ORPN.OQ on NASDAQ Stock Exchange Capital Market

2.81USD
3:59pm EST
Change (% chg)

$0.03 (+1.08%)
Prev Close
$2.78
Open
$2.77
Day's High
$2.82
Day's Low
$2.77
Volume
1,550
Avg. Vol
45,809
52-wk High
$6.05
52-wk Low
$1.64

Latest Key Developments (Source: Significant Developments)

Bioblast Pharma reports Q3 loss per share $0.32
Thursday, 2 Nov 2017 07:30am EDT 

Nov 2 (Reuters) - Bioblast Pharma Ltd :Bioblast Pharma reports third quarter 2017 financial results.Q3 loss per share $0.32.  Full Article

Bioblast announces effectiveness of five to one reverse split
Monday, 25 Sep 2017 07:00am EDT 

Sept 25 (Reuters) - Bioblast Pharma Ltd :Bioblast announces effectiveness of five to one reverse split.Bioblast Pharma - ‍trading of ordinary shares on NASDAQ Capital Market will continue, on a split-adjusted basis, with opening of market on Monday​.  Full Article

Bioblast Pharma reports Q2 loss per share $0.10
Friday, 4 Aug 2017 04:15pm EDT 

Aug 4 (Reuters) - Bioblast Pharma Ltd -:Bioblast Pharma reports second quarter 2017 financial results.Q2 loss per share $0.10.Bioblast Pharma Ltd - ‍ Colin Foster and Ralf Rosskamp, MD, have submitted their resignations as members of board, effective August 31, 2017​.  Full Article

Bioblast Pharma to seek strategic alternatives including partnership and merger
Monday, 5 Jun 2017 04:15pm EDT 

June 5 (Reuters) - Bioblast Pharma Ltd ::Bioblast Pharma to seek strategic alternatives including partnership and merger opportunities.Bioblast Pharma Ltd - company receives regulatory clearance to initiate a phase 2b trial of trehalose in opmd patients.Bioblast-At present, ‍not encumbered by license, partnership or royalty arrangements with third parties for development,commercialization of trehalose​.Bioblast Pharma Ltd- it has engaged jsb-partners, a global life sciences advisor, to assist company in executing its "business development objectives".  Full Article

Bioblast Pharma Q1 loss per share $0.16
Friday, 26 May 2017 04:15pm EDT 

May 26 (Reuters) - Bioblast Pharma Ltd :Bioblast pharma reports first quarter 2017 financial results.Q1 loss per share $0.16.Bioblast pharma ltd says pre-commercial expenses were $0.4 million for quarter ended march 31, 2017, compared to $0.8 million for same period in 2016.Bioblast pharma ltd - qtrly loss per share $0.16.Bioblast pharma- cash, cash equivalents and short-term bank deposits as of march 31, 2017, were $7.1 million, compared to $9.9 million as of december 31, 2016.Bioblast pharma ltd - "should we be unable to obtain additional funding required to continue our clinical activity".Bioblast pharma ltd - "we may need to reduce our activities and to explore strategic alternatives until we have sufficient resources".Bioblast pharma ltd - additional funding beyond existing cash resources will be required to entirely cover cost of phase 2b clinical study.  Full Article

Bioblast Pharma posts Q4 loss per share of $0.19
Friday, 24 Feb 2017 08:00am EST 

Bioblast Pharma Ltd : Bioblast pharma reports fourth quarter and year end 2016 financial results . Q4 loss per share $0.19 .Bioblast pharma ltd - cash, cash equivalents and short-term bank deposits as of December 31, 2016 were $9.9 million.  Full Article

Bioblast Pharma reports Q2 loss per share $0.22
Thursday, 25 Aug 2016 08:00am EDT 

Bioblast Pharma Ltd : Bioblast Pharma reports second quarter 2016 financial results .Q2 loss per share $0.22.  Full Article

Bio Blast Pharma updates corporate plans
Thursday, 9 Jun 2016 06:00am EDT 

Bio Blast Pharma Ltd : Says Fredric Price, executive chairman, will lead company's day-to-day operational efforts . Intends to enroll more than 70 patients in phase 2B clinical trial at up to 15 sites in United States and Canada . Plans to initiate a phase 2B trial with trehalose IV solution in OPMD during second half of 2016 . Colin Foster, Bioblast's president and CEO, will be leaving his operational position . Made decision to streamline company expenditures and downsize management team . Up to 8 employees have left or will be leaving co, including chief commercial officer, chief corporate development officer, CFO .Bio Blast Pharma updates corporate plans.  Full Article

Bioblast Pharma reports Q1 loss per share $0.32
Wednesday, 25 May 2016 08:00am EDT 

Bio Blast Pharma Ltd : Bioblast Pharma reports first quarter 2016 financial results .Q1 loss per share $0.32.  Full Article

Bio Blast Pharma Ltd announces pricing of $6.7 mln Registered Direct Offering
Thursday, 17 Mar 2016 07:00am EDT 

Bio Blast Pharma Ltd:Says has entered into definitive securities purchase agreements with two healthcare focused institutional investors providing for the issuance of about 2.16 million ordinary shares at a purchase price per share of $3.10.Roth Capital Partners and Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as the exclusive placement agents for this transaction.  Full Article

BRIEF-Bioblast Pharma reports Q3 loss per share $0.32

* Bioblast Pharma reports third quarter 2017 financial results